Foundation Medicine

Foundation Medicine, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in genomic profiling products aimed at enhancing cancer treatment. The company provides a range of clinical products, including FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies, which utilize advanced genetic sequencing technology to identify personalized therapy options for patients. Its molecular information platform offers insights into the genetic alterations associated with various cancers, enabling healthcare providers to make informed treatment decisions. Foundation Medicine also collaborates with pharmaceutical companies, such as Roche and Genentech, to develop targeted therapies and companion diagnostics, thereby fostering advancements in precision medicine. Additionally, the company maintains partnerships with organizations like The European Organisation for Research and Treatment of Cancer to facilitate clinical trial participation and improve patient care through integrated genomic profiling. Founded in 2009, Foundation Medicine is a subsidiary of Roche Holdings, Inc.

Daniel Malarek

CEO

Aaron Dungca Needham

Senior Analyst Business Operations and Customer Experience

2 past transactions

Lexent Bio

Acquisition in 2020
LEXENT BIO, INC. develops liquid biopsy technology for the treatment of cancer. It provides clinically actionable information about cancer diagnosis and treatment, and lets clinicians monitor response to the therapy. The company was incorporated in 2014 and is based in San Francisco, California. As of June 12, 2020, LEXENT BIO, INC. operates as a subsidiary of Foundation Medicine, Inc.

COTA

Series B in 2016
COTA, Inc. is a Boston-based company that specializes in developing a platform designed to provide data and insights related to cancer patients, aimed at guiding treatment decisions. Founded in 2011 by a team of doctors, engineers, and data scientists, COTA utilizes proprietary technology and advanced analytics to transform fragmented electronic health record (EHR) data into cohesive, research-grade information. This platform supports oncology practices and cancer centers by identifying variations in care, thus enabling the design of effective treatment programs and payment models. COTA's solutions serve a diverse range of stakeholders, including healthcare providers, payers, life sciences companies, and the FDA, ultimately striving to enhance patient outcomes and reduce healthcare costs associated with cancer care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.